Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) rose 52.1% on Friday . The company traded as high as C$0.55 and last traded at C$0.37. Approximately 206,079 shares changed hands during mid-day trading, an increase of 1,572% from the average daily volume of 12,326 shares. The stock had previously closed at C$0.24.
Aptose Biosciences Stock Performance
The company’s 50-day moving average price is C$0.41 and its two-hundred day moving average price is C$0.66. The company has a market cap of C$7.61 million, a P/E ratio of -0.07 and a beta of 1.36. The company has a current ratio of 0.80, a quick ratio of 5.41 and a debt-to-equity ratio of 670.80.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- Stock Analyst Ratings and Canadian Analyst Ratings
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- Investing in Travel Stocks Benefits
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
